- ￥290 - 1990
- Solarbio
- 北京
- IS3730
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
SC-514
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
354812-17-2
- 规格：
100mg/50mg/10mg/5mg
| 规格： | 100mg | 产品价格： | ￥1990.0 |
|---|---|---|---|
| 规格： | 50mg | 产品价格： | ￥1290.0 |
| 规格： | 10mg | 产品价格： | ￥540.0 |
| 规格： | 5mg | 产品价格： | ￥290.0 |
| 基本信息 | |
| CAS | No.354812-17-2 |
| 英文名称 | SC-514 |
| 别名 | GK 01140; |
| 分子式 | C9H8N2OS2 |
| 分子量 | 224.3 |
| 溶解性 | Soluble in DMSO(Need ultrasonic) |
| 纯度 | ≥98% |
| 外观(性状) | Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD00206459 |
| SMILES | C1=CSC=C1C2=CC(=C(S2)C(=O)N)N |
| InChIKey | BMUACLADCKCNKZ-UHFFFAOYSA-N |
| InChI | InChI=1S/C9H8N2OS2/c10-6-3-7(5-1-2-13-4-5)14-8(6)9(11)12/h1-4H，10H2，(H2，11，12) |
| PubChem CID | 2807869 |
| 靶点 | IKK2 |
| 通路 | NF-κB |
| 背景说明 | SC-514 是一种选择性 IKK-2 抑制剂 。 |
| 生物活性 | SC-514 is a selective IKK-2 inhibitor (IC50=11.2 μM)， which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.[1][2] |
| IC50 | IC50: 11.2 μM (IKK-2);61 μM (CDK2/A);71 μM (AUR2);75 μM (PRAK);123 μM (MSK)[1] |
| In Vitro | SC-514 inhibits the native IKK complex or recombinant human IKK-1/IKK-2 heterodimer with IC50s of 6.1±2.2 μM and 2.7±0.7 μM， respectively. IKK-2 inhibition by SC-514 is selective， reversible， and competitive with ATP. SC-514 inhibits transcription of NF-κB-dependent genes in IL-1β-induced rheumatoid arthritis-derived synovial fibroblasts in a dose-dependent manner. SC-514 inhibits all forms of recombinant human IKK-2 including rhIKK-2 homodimer， rhIKK-1/rhIKK-2 heterodimer， as well as the constitutively active form of rhIKK-2 with comparable IC50 values in the 3-12 μM range[1]. To evaluate whether the reactive oxygen species (ROS)-inducing IKKβ inhibitor increases the sensitivity of melanoma cells to nitrosourea. The responses of melanoma cells are first assessed to SC-514/Fotemustine co-treatment. Melanoma cell lines are treated with 50 μM of SC-514 and Fotemustine alone and in combination for 48 h and growth inhibition is assessed. Co-treatment with SC-514 significantly enhances Fotemustine-induced cytotoxicity in all melanoma cell lines tested[2]. |
| 细胞实验 | SC-514 is efficacious in an acute model of inflammation， namely LPS-induced serum TNFα production in the rat. SC-514 shows a dose-dependent inhibition of TNFα production， validating IKK-2 as a potential anti-inflammatory drug target in vivo[1]. To obtain in vivo evidence for the implication of SC-514 in the response of cancer cells to Fotemustine， the xenograft mouse model of melanoma is used. Nude mice engrafted with A375 or G361 tumors are treated with vehicle control and 25 mg/kg SC-514 and/or 25 mg/kg Fotemustine daily for 13-15 consecutive days and the tumor behavior is monitored. Fotemustine treatment with SC-514 shows a clear combined effect and reduces the size of tumors in mice[2]. |
| 细胞实验 | For crystal violet staining assay， melanoma cell lines (1×104) are seeded in 60 mm dishes， and then untreated or pretreated with SC-514 (50 μM) and/or Fotemustine. Then， cells are formalin-fixed and stained with crystal violet. Cell numbers are measured as the optical density at 595 nm (OD595) of solubilized crystal violet from formalin-fixed cells. Cytotoxicity are also determined by the MTT reduction assay[2]. |
| 动物实验 | Rats[1]:SC-514 or vehicle (2% Me2SO in saline) is administered either by oral gavage (50 mg/kg) or intraperitoneally (10 and 50 mg/kg) to adult male Wistar rats that have been deprived of food overnight. Two hours after compound treatment， 1 mg/kg LPS (Escherichia coli) in saline is administered intraperitoneally 90 min after LPS administration; the animals are bled and serum TNFα levels analyzed by a rat-specific TNFα ELISA.Mice[2]:Male nu/nu BALB/c mice (6 weeks old) are maintained in individual ventilated cages. A375 or G361 (5×106) cells are resuspended in 0.1 mL PBS and inoculated subcutaneously into the backs of nude mice and allowed to grow for 7 days. After that， mice are randomly assigned to 4 groups (n=6 for each group) and treated by intraperitoneal injection with 200 μL 30% PEG/5% Tween-80 solution as the vehicle control and 25 mg/kg SC-514 and/or 25 mg/kg Fotemustine daily for 13-15 consecutive days. Body weight and tumor volume are measured every 3 days. Tumor volumes are determined by a caliper and calculated. At the end of the experiment， mice are sacrificed and tumor xenografts are collected. Tumor tissues are stored at -80°C for Western blot analysis. |
| 激酶实验 | KK complexes are immunoprecipitated from IL-1β-treated RASF cell lysates (0.5-2 mg) using a NEMO antibody (3-10 μg) followed by the addition of protein A-agarose beads. Antibody complexes are pelleted by centrifugation and washed 3 times with 1 mL of cold whole-cell lysis buffer followed by 2 washes in kinase buffer (25 mM HEPES， pH 7.6， 2 mM MgCl2， 2 mM MnCl2， 10 mM NaF， 5 mM DTT， and 1 mM phenylmethylsulfonyl fluoride). 100-200 μg of immunoprecipitated IKK is analyzed for kinase activity in a reaction containing 10 μM biotinylated IκBα peptide as substrate and 1 μM [γ-33P]ATP (2500 Ci/mmol). After incubation at room temperature for 30 min， 25 μL of the reaction mixture is withdrawn and added to a SAM 96 biotin capture plate. After successive wash steps the plate was allowed to air-dry， and 25 μL of scintillation fluid is added to each well. Incorporation of [γ-33P]ATP is measured using a Top-Count NXT[1]. |
| 数据来源文献 | [1]. Kishore N， et al. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J Biol Chem. 2003 Aug 29;278(35):32861-71. [2]. Tse AK， et al. Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition. Redox Biol. 2017 Apr;11:562-576. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
Figure 7.15.3 Electron density maps for the complex between sc Pol η1‐513 and a DNA duplex containing the 5′‐Cy5‐labeled primer are consistent with partially ordered DNA. Superimposed Fourier (2F o ‐F c ) sum
2F+DwTquooTcizAj6Sh40arj1e+iWJ2ispgsbT801bWi9OaaVDQ0u7N9Rf22Q7je3ypEkT/aXtAx/4gHh20RbetchuWXizve3YY/3L0LGHHqt8Cva+97zf/vEfvyYb4imWXpTxLz8m4rvgjodswc3X26Xnn2o3LbjZPv/Fv5GGuGa33/ZzO2n2HD17NAEWeUXwmQh44uy32U+uutL+69e+6jjedfsddvSxx3m8xNNFQ67wipqQKHyESZ35
5+YiLLj4HREBXstjztk7uH3PDncf2sPhxRlMq6wGF+vZ2OlE8VGoBH85gWn/XYBn2ck48eAqDu+xwjbrU7h2Zz2aZ3fD6YWWeBFuzJv2yfAMMyYBFj4y5r7yqpgAE0jPBFRyolzbpihAeo1X9z5K2o2YlqOUxRTN25rQLQ+8+x4oVfFzvgFHklZM2raEadaIsxjVfI0wedUizB5fB7r8yR8TTr6mQAL8FlQgbB6KCTABJiAfgWD8ev0cIrh
技术资料暂无技术资料 索取技术资料
IS3730 SC-514 抑制剂/拮抗剂/激动剂 索莱宝
￥290 - 1990
